Previous close | 14.79 |
Open | 14.32 |
Bid | 14.90 x 4600 |
Ask | 14.93 x 2300 |
Day's range | 14.06 - 15.69 |
52-week range | 3.53 - 15.69 |
Volume | |
Avg. volume | 13,084,566 |
Market cap | 2.196B |
Beta (5Y monthly) | 1.62 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
After disappointing sales for their Covid vaccines last year, drugmakers are hoping for an August rollout of the updated shot.
Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 million at a lofty valuation. Novavax, which struggled to get its protein-based vaccine to the market in a timely manner, also removed a warning notice from February last year that raised doubts about it being in business after the deal. The fund, which owns an about 7.8% stake in Novavax, reiterated that the Sanofi agreement was a "long-awaited step in the right direction".
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.